RecruitingPhase 1NCT07239323

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing Precision Biotech Co., Ltd
Principal Investigator
Wang Sanbin, MD
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Intervention
Invivo CAR-T(biological)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07239323 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials